Biogen Idec (NQ:BIIB)

219.88 -2.94 (-1.32%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

62 63 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

June 16, 2026

From Pomerantz LLP

Via GlobeNewswire

3 Overrated Stocks Walking a Fine Line

June 15, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

Via StockStory

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

June 10, 2026

From Schall Law

Via GlobeNewswire

1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky

June 10, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

Unusual volume S&P500 stocks in Thursday's session ↗

May 14, 2026

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

June 09, 2026

From Pomerantz LLP

Via GlobeNewswire

Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. ↗

June 05, 2026

Can the drugmaker justify its valuation?

Via The Motley Fool

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

June 04, 2026

From The Schall Law Firm

Via Business Wire

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

June 04, 2026

From Biogen Inc.

Via GlobeNewswire

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

June 04, 2026

From Biogen Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

June 02, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

May 26, 2026

From Pomerantz LLP

Via GlobeNewswire

MarketBeat Week in Review – 05/18 - 05/22 ↗

May 23, 2026

Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports

Via MarketBeat

Topics Artificial Intelligence Economy

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish ↗

May 22, 2026

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock

Via MarketBeat

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

May 21, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud

May 19, 2026

From Levi & Korsinsky, LLP

Via Business Wire

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push ↗

May 14, 2026

Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam...

Via MarketBeat

Stay informed with the top movers within the S&P500 index on Thursday. ↗

May 14, 2026

Via Chartmill

Best Healthcare Stocks to Buy in 2026 ↗

May 14, 2026

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

Via The Motley Fool

Thursday's session: top gainers and losers in the S&P500 index ↗

May 14, 2026

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

May 14, 2026

Via Chartmill

Discover the top S&P500 movers in Thursday's pre-market session. ↗

May 14, 2026

Via Chartmill

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

May 14, 2026

CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development

From Biogen Inc.

Via GlobeNewswire

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

May 11, 2026

Via Investor Brand Network

InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates

May 11, 2026

Via Investor Brand Network

Topics Intellectual Property

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

May 11, 2026

From BioMedWire

Via GlobeNewswire

3 Healthcare Stocks We’re Skeptical Of

May 11, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-...

Via StockStory

3 Value Stocks We Approach with Caution

May 08, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Via StockStory

Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings ↗

April 30, 2026

Biogen (NASDAQ:BIIB) reported strong Q1 earnings, beating expectations. However, they cut their FY2026 EPS guidance. Analysts have mixed opinions on buying BIIB stock.

Via Benzinga

Why Biogen Stock Was a Winner on Wednesday ↗

April 29, 2026

The biotech's growth portfolio continues to add to its overall top line.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.